Sanofi buys haemophilia specialist for $11.6 bn

ReutersNewsPublished: January 22, 2018
Published: January 22, 2018

Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion. As Silvia Antonioli reports, the French healthcare group says the deal will boost earnings and strengthen its presence in treatments for rare diseases.

Be the first to suggest a tag

    Comments

    0 comments